| status | count |
|---|---|
| PASS | 55 |
| indicator | control_group | combination_therapy_group | statistic_value | p_value | test |
|---|---|---|---|---|---|
| Age (years) | 52.38 +/- 5.84 | 53.16 +/- 5.02 | t = 0.716 | 0.476 | Independent-samples t test |
| Time from onset to visit (days) | 4.28 +/- 0.53 | 4.42 +/- 0.51 | t = 1.347 | 0.181 | Independent-samples t test |
| Baseline PTA-4 (dB HL) | 69.45 +/- 7.64 | 70.16 +/- 7.32 | t = 0.474 | 0.636 | Independent-samples t test |
| Sex (male/female, n, %) | 27 (54 %) / 23 (46 %) | 25 (50 %) / 25 (50 %) | chi-square = 0.160 | 0.689 | Chi-square test |
| Side of affected ear (left/right, n, %) | 26 (52 %) / 24 (48 %) | 23 (46 %) / 27 (54 %) | chi-square = 0.360 | 0.548 | Chi-square test |
| History of hypertension (n, %) | 11 (22 %) | 9 (18 %) | chi-square = 0.250 | 0.617 | Chi-square test |
| time_point | control_group | combination_therapy_group | mean_difference_95ci | t_value | p_value | cohens_d |
|---|---|---|---|---|---|---|
| Baseline | 69.45 +/- 7.64 | 70.16 +/- 7.32 | 0.71 (-2.26 to 3.68) | 0.474 | 0.636 | 0.095 |
| Day 10 | 63.21 +/- 7.02 | 60.85 +/- 6.28 | -2.36 (-5.00 to 0.28) | 1.772 | 0.080 | 0.354 |
| Day 30 | 57.44 +/- 6.51 | 55.12 +/- 5.94 | -2.32 (-4.79 to 0.15) | 1.861 | 0.066 | 0.372 |
| Day 90 | 52.36 +/- 6.07 | 48.79 +/- 5.66 | -3.57 (-5.90 to -1.24) | 3.041 | 0.003 | 0.608 |
| Group x time interaction | F = 19.535, p = <0.001 | NaN | NaN | NaN | NaN | NaN |
| hearing_grade | time_point | control_group_n_percent | combination_therapy_group_n_percent | statistic_value | p_value | test |
|---|---|---|---|---|---|---|
| Mild | NaN | NaN | NaN | NaN | NaN | NaN |
| NaN | Baseline | 3 (6.0 %) | 2 (4.0 %) | chi-square = 0.211 | 0.646 | Chi-square test |
| NaN | Day 90 | 8 (16.0 %) | 15 (30.0 %) | chi-square = 2.767 | 0.096 | Chi-square test |
| Moderate | NaN | NaN | NaN | NaN | NaN | NaN |
| NaN | Baseline | 12 (24.0 %) | 9 (18.0 %) | chi-square = 0.542 | 0.461 | Chi-square test |
| NaN | Day 90 | 21 (42.0 %) | 23 (46.0 %) | chi-square = 0.162 | 0.687 | Chi-square test |
| Severe | NaN | NaN | NaN | NaN | NaN | NaN |
| NaN | Baseline | 21 (42.0 %) | 26 (52.0 %) | chi-square = 1.004 | 0.316 | Chi-square test |
| NaN | Day 90 | 15 (30.0 %) | 9 (18.0 %) | chi-square = 1.974 | 0.160 | Chi-square test |
| Profound | NaN | NaN | NaN | NaN | NaN | NaN |
| NaN | Baseline | 14 (28.0 %) | 13 (26.0 %) | chi-square = 0.051 | 0.822 | Chi-square test |
| NaN | Day 90 | 6 (12.0 %) | 3 (6.0 %) | chi-square = 1.099 | 0.295 | Chi-square test |
| dimension | time_point | control_group | combination_therapy_group | mean_difference_95ci | t_value | p_value | cohens_d |
|---|---|---|---|---|---|---|---|
| PF | Baseline | 55.27 +/- 4.95 | 54.62 +/- 5.14 | -0.65 (-2.65 to 1.35) | 0.644 | 0.521 | 0.129 |
| NaN | Day 30 | 62.13 +/- 5.11 | 66.59 +/- 5.43 | 4.46 (2.37 to 6.55) | 4.229 | <0.001 | 0.846 |
| NaN | Day 90 | 68.45 +/- 5.77 | 74.51 +/- 6.09 | 6.06 (3.71 to 8.41) | 5.108 | <0.001 | 1.022 |
| NaN | Group x time interaction | F = 6.951, p = <0.001 | NaN | NaN | NaN | NaN | NaN |
| RP | Baseline | 50.96 +/- 6.28 | 51.44 +/- 6.01 | 0.48 (-1.96 to 2.92) | 0.390 | 0.698 | 0.078 |
| NaN | Day 30 | 58.27 +/- 5.94 | 60.69 +/- 6.23 | 2.42 (0.00 to 4.84) | 1.988 | 0.050 | 0.398 |
| NaN | Day 90 | 63.41 +/- 6.32 | 68.15 +/- 5.98 | 4.74 (2.30 to 7.18) | 3.851 | <0.001 | 0.770 |
| NaN | Group x time interaction | F = 3.770, p = 0.012 | NaN | NaN | NaN | NaN | NaN |
| BP | Baseline | 57.83 +/- 4.89 | 58.64 +/- 5.27 | 0.81 (-1.21 to 2.83) | 0.796 | 0.428 | 0.159 |
| NaN | Day 30 | 63.25 +/- 5.24 | 66.16 +/- 5.48 | 2.91 (0.78 to 5.04) | 2.714 | 0.008 | 0.543 |
| NaN | Day 90 | 68.42 +/- 5.93 | 72.57 +/- 5.86 | 4.15 (1.81 to 6.49) | 3.520 | <0.001 | 0.704 |
| NaN | Group x time interaction | F = 3.258, p = 0.023 | NaN | NaN | NaN | NaN | NaN |
| GH | Baseline | 52.41 +/- 5.01 | 53.26 +/- 5.57 | 0.85 (-1.25 to 2.95) | 0.803 | 0.424 | 0.161 |
| NaN | Day 30 | 59.07 +/- 5.18 | 61.42 +/- 5.44 | 2.35 (0.24 to 4.46) | 2.212 | 0.029 | 0.442 |
| NaN | Day 90 | 64.69 +/- 5.35 | 69.45 +/- 5.87 | 4.76 (2.53 to 6.99) | 4.238 | <0.001 | 0.848 |
| NaN | Group x time interaction | F = 5.316, p = 0.002 | NaN | NaN | NaN | NaN | NaN |
| VT | Baseline | 54.39 +/- 4.96 | 53.72 +/- 4.64 | -0.67 (-2.58 to 1.24) | 0.698 | 0.487 | 0.140 |
| NaN | Day 30 | 60.11 +/- 5.45 | 64.38 +/- 5.22 | 4.27 (2.15 to 6.39) | 4.000 | <0.001 | 0.800 |
| NaN | Day 90 | 66.24 +/- 5.67 | 71.56 +/- 6.18 | 5.32 (2.97 to 7.67) | 4.485 | <0.001 | 0.897 |
| NaN | Group x time interaction | F = 5.665, p = <0.001 | NaN | NaN | NaN | NaN | NaN |
| SF | Baseline | 58.61 +/- 5.22 | 59.38 +/- 4.88 | 0.77 (-1.24 to 2.78) | 0.762 | 0.448 | 0.152 |
| NaN | Day 30 | 63.72 +/- 5.35 | 67.21 +/- 5.43 | 3.49 (1.35 to 5.63) | 3.238 | 0.002 | 0.648 |
| NaN | Day 90 | 69.08 +/- 5.74 | 73.48 +/- 6.03 | 4.40 (2.06 to 6.74) | 3.736 | <0.001 | 0.747 |
| NaN | Group x time interaction | F = 3.900, p = 0.010 | NaN | NaN | NaN | NaN | NaN |
| RE | Baseline | 55.02 +/- 5.41 | 55.67 +/- 5.84 | 0.65 (-1.58 to 2.88) | 0.578 | 0.565 | 0.116 |
| NaN | Day 30 | 61.35 +/- 5.52 | 64.83 +/- 5.95 | 3.48 (1.20 to 5.76) | 3.032 | 0.003 | 0.606 |
| NaN | Day 90 | 66.78 +/- 5.64 | 71.84 +/- 5.32 | 5.06 (2.88 to 7.24) | 4.614 | <0.001 | 0.923 |
| NaN | Group x time interaction | F = 7.095, p = <0.001 | NaN | NaN | NaN | NaN | NaN |
| MH | Baseline | 56.18 +/- 5.06 | 55.72 +/- 5.23 | -0.46 (-2.50 to 1.58) | 0.447 | 0.656 | 0.089 |
| NaN | Day 30 | 62.09 +/- 5.51 | 65.36 +/- 5.88 | 3.27 (1.01 to 5.53) | 2.870 | 0.005 | 0.574 |
| NaN | Day 90 | 67.42 +/- 5.81 | 72.39 +/- 6.02 | 4.97 (2.62 to 7.32) | 4.201 | <0.001 | 0.840 |
| NaN | Group x time interaction | F = 4.237, p = 0.006 | NaN | NaN | NaN | NaN | NaN |
| time_point | control_group | combination_therapy_group | mean_difference_95ci | t_value | p_value | cohens_d |
|---|---|---|---|---|---|---|
| Baseline | 72.63 +/- 6.85 | 71.84 +/- 6.42 | -0.79 (-3.42 to 1.85) | 0.595 | 0.553 | 0.119 |
| Day 10 | 64.58 +/- 6.01 | 60.23 +/- 6.14 | -4.35 (-6.76 to -1.94) | 3.579 | <0.001 | 0.716 |
| Day 30 | 56.42 +/- 5.58 | 51.37 +/- 5.44 | -5.05 (-7.24 to -2.86) | 4.583 | <0.001 | 0.917 |
| Day 90 | 48.06 +/- 5.12 | 41.12 +/- 4.68 | -6.94 (-8.89 to -4.99) | 7.074 | <0.001 | 1.415 |
| Group x time interaction | F = 18.105, p = <0.001 | NaN | NaN | NaN | NaN | NaN |
| adverse_reaction_type | control_group_n_percent | combination_therapy_group_n_percent | statistic_value | p_value | test |
|---|---|---|---|---|---|
| Headache | 6 (12.0 %) | 4 (8.0 %) | chi-square = 0.444 | 0.505 | Chi-square test |
| Dizziness | 4 (8.0 %) | 5 (10.0 %) | chi-square = 0.122 | 0.727 | Chi-square test |
| Nausea | 5 (10.0 %) | 3 (6.0 %) | chi-square = 0.543 | 0.461 | Chi-square test |
| Rash | 2 (4.0 %) | 1 (2.0 %) | chi-square = 0.344 | 0.558 | Chi-square test |
| Blood pressure fluctuation | 3 (6.0 %) | 1 (2.0 %) | chi-square = 1.042 | 0.307 | Chi-square test |
| Other serious adverse event | 1 (2.0 %) | 0 (0.0 %) | Fisher | 1.000 | Fisher exact test |
| 0 | 1 |
|---|---|
| SSNHL_analysis_dataset.csv | Created |
| SSNHL_pta4_long.csv | Created |
| SSNHL_sf36_long.csv | Created |
| SSNHL_hhia_long.csv | Created |
| SSNHL_adverse_event_flags.csv | Created |
| SSNHL_analysis_syntax.sps | Created |
| SSNHL_statistical_output.spv | Not created: PSPP/SPSS not available in this environment |